MD Anderson Cancer Center at Cooper has joined a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery. This study, done in conjunction with The University of Texas MD Anderson Cancer Center in Houston, is led by principal investigator Henry M. Read more.
Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.
“CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health,” said John A. Read more.
On Tuesday, October 9, 2018, a team from Cooper’s Infection Prevention department visited the Cathedral Kitchen in Camden. Led by Shahrzad Darvish, MSN, RN, CIC, the team volunteered to plate and serve dinner to 330 guests that evening, as well as clean-up assignments after dinner.
“It was lots of fun and everyone felt good,” said Darvish. “The volunteer in charge was impressed to see a department from Cooper health helping out; they wanted to know what we do and who we are. Read more.
MD Anderson Cancer Center at Cooper has received a three-year approval to establish a new Breast Surgical Oncology Fellowship Program by the Society of Surgical Oncology, one of fewer than 50 programs in the nation.
“Receiving approval from the Society of Surgical Oncology for this new fellowship affirms the quality of the curriculum and the faculty at MD Anderson at Cooper,” said Kristin L. Read more.
The results of a five-year, international multicenter trial studying the efficacy of a “blood purification” technique to treat sepsis has been published today in The Journal of the American Medical Association, a leading medical journal. Cooper University Health Care was the flagship investigative center and also the coordinating center for the study. Read more.
On Friday, September 21, 2018, MD Anderson Cancer Center at Cooper in conjunction with U.S. Congressman Donald Norcross (NJ-01) participated in the Biden Cancer Community Summit to hear local perspectives on treatment, proposals for federal actions, and personal stories from a panel of cancer survivors, family caregivers, doctors, and nurses.
“In this midst of our daily work, it’s important to pause and discuss these vital issues. Read more.
Cooper is one of approximately 40 sites in the United States and the only hospital in the Philadelphia region participating in a clinical trial for Boston Scientific’s WATCHMAN FLX™ device. The WATCHMAN FLX™ is the next generation of a potentially life-changing catheter-based (or non-surgically delivered) device designed to close the left atrial appendage in order to reduce the risk of stroke in certain patients with atrial fibrillation (AFib). Read more.
On Friday, September 28, 2018, Lourdes Alanis, a fourth-year resident with Cooper’s Diagnostic Radiology program, gave Instagram followers a look into the world of interventional radiology (IR). This opportunity was provided by the Society of Interventional Radiology (SIR), which highlighted six women in IR as part of a social media campaign in September celebrating Women in Medicine Month. Each physician shared photos on SIR’s Instagram, walking followers through their “day in the life” at various institutions across the country. Read more.
Updated visiting hours image: December 13, 2018
In our continuous effort to enhance patient care and improve the Cooper experience for our patients and employees, guest visiting hours at the hospital now end at 9 p.m., which was made effective Monday, September 24, 2018. This change is consistent with other hospitals in the region. Click here to see visiting hours throughout the hospital. Read more.
MD Anderson Cancer Center at Cooper marked its five-year anniversary of serving the region at a celebration attended by elected officials, hospital leadership, and cancer survivors.
“This is another exciting day as MD Anderson at Cooper continues to transform cancer care for the people of South Jersey and the region,” said George E. Norcross III, Chairman of the Board of Trustees at Cooper University Health Care. Read more.